GIGAGEN
GigaGen is advancing a pipeline of first-in-class biotherapeutics, including novel oncology antibody drug combinations and the world’s first recombinant polyclonal hyperimmune gammaglobulin. Behind our diverse and growing pipeline is a mission to bring forth a new generation of highly efficacious drugs, driven by an unparalleled understanding of immune dysregulation. Our proprietary antibody discovery technology quickly characterizes every cell in complex immune systems, powering our selection of drug targets, identification of drug candidates and preclinical assessment of efficacy.
GIGAGEN
Industry:
Biotechnology Genetics Medical Therapeutics
Founded:
2010-03-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.gigagen.com
Total Employee:
11+
Status:
Active
Contact:
(415)978-2101
Email Addresses:
[email protected]
Total Funding:
38.43 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Benitec Ltd
Benitec Biopharma is using patented ‘gene-silencing’ technology to develop drugs for chronic and life-threatening human diseases.
CirculoGene Theranostics
CirculoGene specializes in the fields of cfDNA, liquid biopsy, tumor monitoring, laboratory testing, and molecular diagnostics.
New England Biolabs
New England Biolabs is focused on the discovery and development of recombinant and native enzymes for genomic research.
Perlara
Perlara, PBC is precision drug discovery that leaves no mutation behind.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Sino-Biocan
Sino-Biocan focuses on the research and development of domestic tools in the field of cell and gene therapy.
Current Advisors List
Current Employees Featured
Founder
Investors List
Grifols
Grifols investment in Funding Round - GigaGen
National Science Foundation
National Science Foundation investment in Grant - GigaGen
Official Site Inspections
http://www.gigagen.com Semrush global rank: 4.45 M Semrush visits lastest month: 2.47 K
- Host name: 143.7.209.35.bc.googleusercontent.com
- IP address: 35.209.7.143
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "GigaGen"
GigaGen - Crunchbase Company Profile & Funding
GigaGen is advancing a pipeline of first-in-class biotherapeutics, including novel oncology antibody drug combinations and the world’s first recombinant polyclonal hyperimmune gammaglobulin. Behind our diverse and growing pipeline is a …See details»
Grifols reinforces its innovation strategy after completing the ...
Mar 9, 2021 GigaGen: R+D focused on developing the world’s first recombinant polyclonal immunoglobulin. Headquartered in San Francisco (California, United States), GigaGen is …See details»
GigaGen Inc - LinkedIn
GigaGen Inc | 5,962 followers on LinkedIn. GigaGen, a subsidiary of Grifols, is advancing transformative antibody drugs for immune deficiency, infectious diseases and checkpoint …See details»
GigaGen - Overview, News & Similar companies | ZoomInfo.com
View GigaGen (www.gigagen.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as employees by title and much more. …See details»
GigaGen, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting drug manufacturing and phase 1 trials for the two programs GigaGen’s …See details»
Grifols reinforces its innovation strategy after completing the ...
Mar 9, 2021 GigaGen's lead oncology asset, GIGA-564, is an anti-CTLA-4 monoclonal antibody that has demonstrated improved anti-tumor efficacy in vivo through a unique mechanism of …See details»
GigaGen Company Profile 2024: Valuation, Investors, Acquisition
GigaGen was founded in 2010. Where is GigaGen headquartered? GigaGen is headquartered in San Francisco, CA. What is the size of GigaGen? GigaGen has 39 total employees. What …See details»
Grifols Reinforces Its Innovation Strategy After Completing
BARCELONA, Spain, March 9, 2021 /PRNewswire/ — Grifols (MCE: GRF, MCE: GRF.P;NASDAQ: GRFS), a global healthcare company with a proven track record of more …See details»
Grifols opens new lines of research with the acquisition of a 44
Jul 5, 2017 About GigaGen GigaGen is a biopharmaceutical company that develops novel antibody therapies derived from immune repertoires. GigaGen’s technology platform captures …See details»
GigaGen Closes $50M Deal With Grifols
GigaGen has received $35 million in investment funding and $15 million licensing fee payment from Grifols. Read the full story from Endpoints: An upstart in the polyclonal antibody biz just …See details»
Gigagen, Inc. | SBIR.gov
But for patients suffering from these diseases, there’s no time to lose.The biotherapeutic company GigaGen has developed a new way to screen for drug candidates, with the... Award Charts ...See details»
GigaGen Company Profile - Office Locations, Competitors ... - Craft
GigaGen $37.6 m in total funding,. See insights on GigaGen including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Pharmaceutical Company Aims to Develop Better Drugs for …
Mar 16, 2020 The biotherapeutic company GigaGen has developed a new way to screen for drug candidates, with the promise that it will lead to the discovery of more potent, less toxic …See details»
GigaGen Receives FDA Clearance of IND to Begin Phase 1 Trial of ...
Dec 12, 2023 GigaGen, Inc. The Phase 1 trial will be conducted by researchers from the National Cancer Institute as part of a Cooperative Research and Development Agreement …See details»
GigaGen Doses First Patient in Phase 1 Trial of Recombinant …
Aug 11, 2021 First-in-human study evaluating recombinant hyperimmunes SOUTH SAN FRANCISCO, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology …See details»
GigaGen Publishes Research on Company’s Recombinant …
Apr 15, 2021 South San Francisco, Calif., April 15, 2021 (GLOBE NEWSWIRE) - GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, …See details»
GigaGen Doses First Patient in Phase 1 Trial of Recombinant
Aug 11, 2021 GigaGen is advancing transformative antibody drugs for immune deficiency, infectious diseases and checkpoint resistant cancers by leveraging industry-leading, single-cell …See details»
GigaGen Initiates Large-Scale Manufacturing Of First-in-Class ...
Sep 9, 2020 SOUTH SAN FRANCISCO, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for …See details»
GigaGen Doses First Patient In Phase 1 Trial Of Recombinant …
Aug 11, 2021 SOUTH SAN FRANCISCO, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for …See details»